1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers

Reimbursement Give And Take

 
• By Lisa Takagi

Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.

Cortiment, Litfulo, Lytgobi, Empaveli, Oncaspar, ActHIB and Luxturna joined NHI reimbursement list.
Cortiment, Litfulo, Lytgobi, Empaveli, Oncaspar, ActHIB and Luxturna join Japan NHI reimbursement list. • Source: Shutterstock

Japan has set reimbursement prices for six new drugs under its national health insurance (NHI) scheme - including a gene therapy with the second-highest unit price ever for a therapeutic product in the country - along with one-off price cuts for several other drugs that have shown higher than expected growth.

The Ministry of Health, Labour and Welfare (MHLW) announced that the products set to be added to the NHI reimbursement tariff on 30 August include Taiho Pharmaceutical Co. Ltd.'s FGFR inhibitor Lytgobi (futibatinib), Les Laboratoires Servier's acute lymphoblastic leukemia drug Oncaspar (pegaspargase) and Apellis Pharmaceuticals, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By Lisa Takagi

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.